Thermo Fisher launches biomarker discovery grant program; Metamark rolls out prostate cancer prognosis test;

> Thermo Fisher Scientific ($TMO) said it will fast-track 12 research teams' gene-expression profiling projects focused on biomarker discovery by way of a new grant program. Release

> Arizona's Global Cancer Diagnostics is launching a $99 diagnostic test designed to enable the early detection of lung cancer. Release

> Illumina ($ILMN) will partner with genetic screening and diagnostics company Reprogenetics on in vitro fertilization gene-sequencing/diagnostics development. Story

> Tymora Analytical Operations in Indiana is moving ahead with a new federal grant to study blood plasma for biomarkers that can be a sign of various diseases. Story

> Massachusetts' Metamark has rolled out ProMark, a new protein-based biopsy test designed to give a more accurate prognosis for men diagnosed with prostate cancer. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.